Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Economic Times
The Economic Times
Business

RARE PHOTOS: Sandoz bets big on biosimilars aims to double group sales by 2035 | Rare Historical Photos

Swiss drugmaker Sandoz aims to more than double its annual net sales by 2035, with a majority coming from biosimilar medicines, the company said at its capital markets day ‌on Tuesday.

Biosimilars are ⁠biological drugs ⁠based on existing medicines for which patents have expired. Like generics, they are usually sold at much cheaper prices than patented drugs, as they do not have to ​factor in significant research and development costs.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.